Skip to main navigation Skip to search Skip to main content

Association Between Off-Label Use of Cardio-Kidney-Metabolic Therapies and Risk of Cardiovascular Events in Type 1 Diabetes: A Real-World Evidence Study

  • Ambarish Pandey*
  • , Enrico Repetto
  • , Christopher Perkins
  • , Peter Rossing
  • , M Luiza Caramori
  • *Corresponding author for this work
1 Citation (Scopus)
Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Volume28
Issue number5
Pages (from-to)4352-4355
Number of pages4
ISSN1462-8902
DOIs
Publication statusPublished - May 2026

Keywords

  • cardiovascular disease
  • GLP-1 analogue
  • macrovascular disease
  • real-world evidence
  • SGLT2 inhibitor
  • type 1 diabetes

Cite this